J Studios Thesis I have covered Annovis Bio (NYSE:ANVS) before with a Hold rating in October 2023. At the time, Annovis had not yet released any topline readout from their Phase 3 trial in Parkinson’s and their Phase 2/3 trial in Alzheimer’s. The Phase 2/3 results in Alzheimer’s have just been released. The press release,…
cemagraphics It’s been two weeks since my last article, and there have been some significant developments. On the macro side, “higher for longer” rate expectations are back and the first cut is now expected in September rather than June or July. On the technical side, the S&P 500 (SPY) has finally broken its trend channel…
alfexe/iStock via Getty Images Akero Therapeutics, Inc. (NASDAQ:AKRO) has been able to report positive results from its phase 2b HARMONY study, which used its drug efruxifermin [EFX] for the treatment of patients with pre-cirrhotic MASH or Metabolic dysfunction-associated steatohepatitis with stage 2 or 3 fibrosis. The significance of this is that it is already in…
M. Suhail Thesis Introduction Over the past few months, I have gradually warmed up to the idea that McDonald’s stock (NYSE:MCD) deserves a “Buy” rating. Compared to my previously held “Equal-weight” thesis, which has been published in February 2023, there were two major variables that prompted my rating reassessment: Firstly, I acknowledge that rates are…
koto_feja Intro Annovis Bio (NYSE:ANVS) is set to report the results of its Phase 3 trial in early-stage Parkinson’s disease (PD) in the coming weeks. The company’s lead asset, buntanetap (formerly known as posiphen), is a translational inhibitor of alpha synucelein (associated with PD), amyloid precursor protein (Alzheimer’s), TDP-43 (ALS), and other proteins associated with…
blackdovfx The iShares MSCI Brazil ETF (NYSEARCA:EWZ) continues to outperform its emerging market peers, having risen around 85% relative to the iShares MSCI Emerging Markets ETF (EEM) since its lows in 2021. Since my last article in August, the EWZ has outperformed by a further 11% in total return terms, yet even after these gains,…
Pgiam/iStock via Getty Images Relmada Therapeutics (NASDAQ:RLMD) is a nanocap company developing therapies for CNS diseases. Lead asset is Esmethadone or REL-1017, which functions as a blocker for N-methyl-D-aspartate (NMDA) receptor channels, specifically targeting hyperactive GluN2D channels. NMDA receptors play a crucial role in physiological neural plasticity, and causing various central nervous system (CNS’) disorders,…
Spot Bitcoin ETF applicants have set low fees to attract fund advisors with experts highlighting that custodians will be forced to lower fees to remain competitive in the near future. The race to attract institutional clients to invest in spot Bitcoin Exchange-Traded Funds (ETFs) has trickled down to the specific sponsor fees. With investors having…
kynny Intro We wrote about ADTRAN Holdings, Inc. (NASDAQ:ADTN) back in June of this year when we warned investors that a continuation of the established bearish trend was a clear possibility over the following months. Our premise played itself out with shares of Adtran losing almost 19% of their value over the past 6+ months….
wildpixel Thesis overview Karyopharm’s (NASDAQ:KPTI) lead candidate is selinexor, which has a novel mechanism of action. It acts as a selective inhibitor of nuclear export by binding to exporting 1 (XPO1). KPTI has been the leader in targeting this pathway and has successfully developed selinexor, with 3 approvals so far; in penta-refractory multiple myeloma, in…
tonaquatic Thesis overview MorphoSys AG (NASDAQ:MOR) recently announced positive topline results from its phase 3 trial of pelabresib in myelofibrosis (MF). The study easily met the primary endpoint. However, despite the strong positive trend, statistical significance was not achieved at key secondary endpoints assessing symptomatic improvement. Nevertheless, in a pre-specified subgroup analysis in intermediate-risk patients…
Alex Potemkin/iStock via Getty Images Investment Thesis Company Overview Modine Manufacturing (NYSE:MOD), founded in 1916 and headquartered in Racine, Wisconsin, is a manufacturer and technology provider of thermal management and cooling systems and solutions. Since Q1 of 2023, the company has transitioned to a two-segment structure: Performance Technologies and Climate Solutions. It has the following…
FatCamera/E+ via Getty Images Rezolute – Overview Rezolute (NASDAQ:RZLT) is a clinical-stage biotechnology company focused on metabolic diseases relating to the control of glucose. The lead asset, RZ358, is a human monoclonal antibody that binds to an allosteric site on the insulin receptor and down-regulates the activity of the receptor. The down-regulation of the insulin…
RTimages/iStock via Getty Images When I last wrote about Reviva Pharmaceuticals Holdings (NASDAQ:RVPH) in September, I rated it a buy ahead of upcoming results from the phase 3 RECOVER study of its antipsychotic brilaroxazine in schizophrenia. This article takes a look at the results from RECOVER-1, announced on October 30, and what lies ahead now….
The e-HKD program has taken a three-rail approach for the potential implementation of the virtual currency: foundation layer development, industry pilots and iterative enhancements, and full launch. Hong Kong’s central bank digital currency (CBDC) pilot is set to advance to its second phase following the successful completion of phase one. The first phase was largely…
Cardiac amyloidosis OGphoto Alnylam logo We rate Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) a Buy on the dip after the complete response letter, CRL for Patisiran. The investment thesis is based on the high probability of success for Vutrisiran, the company’s next-generation inverse RNA or RNAi candidate, in treating cardiac amyloidosis in the upcoming Phase 3 Helios-B…
Naeblys The Alzheimer’s Disease (“AD”) space is a very difficult and volatile space right now. Here, you will see a large number of sympathetic volatility in stock prices. So, if one company comes out with positive data, other AD companies go up along with it. If another company has a failed trial, other companies fall….
Pornpak Khunatorn/iStock via Getty Images Thesis NeuroSense (NRSN) is a microcap focused on the treatment of neurodegenerative diseases. It is running a Phase 2b trial in 69 patients diagnosed with ALS, a fast-progressing neurodegenerative disease which is historically difficult to treat, with drug candidate PrimeC. Topline data of this trial are expected in Q4 2023….
AerialPerspective Works By John Lin In an era of new economic challenges, we expect value investing to trump growth-oriented strategies for investors in Chinese equities. Investors are asking tough questions about China as hope for its post-COVID resurgence gives way to concern about its economy. Despite the uncertainties, we think China remains investible and a…
gorodenkoff CymaBay Therapeutics (NASDAQ:CBAY) had made great progress in advancing the use of its drug seladelpar, because it was able to achieve a successful outcome for its phase 3 study known as RESPONSE, which treated patients with primary biliary cholangitis [PBC]. Not only was it able to meet on the primary endpoint, but the secondary…
Sean Anthony Eddy Pharming Group (NASDAQ: NASDAQ:PHAR) stands as a globally recognized biotechnology firm based in the Netherlands. It is best known for its unique approach to addressing rare and genetic diseases. While some may consider their methods unorthodox, their success in the market shows that they are not only viable but also profitable, thus…
gerenme/iStock via Getty Images PDS Biotechnology Corporation (NASDAQ:PDSB) has been able to make great progress with respect to advancing the use of its lead candidate known as PDS0101, which is being developed in combination with Merck’s (MRK) Keytruda to treat certain patients with HPV16-positive head and neck cancer. The last time I spoke about this…
Galeanu Mihai Introduction So far we’ve covered Grab (NASDAQ:GRAB) 7 times since 2021. Throughout our 7 theses, there was a common theme: “Grab’s Leadership Equated To Its Willingness To Spend”. Our verdict was that Grab had to keep spending cash on consumer and partner (drivers) incentives to grow adoption. Should other similar service providers offer…